




Memorandum

TO: Regional Directors, Health Service Regions
Regional Immunization Program Managers, Health Service Regions
Health Department Directors, Local Health Departments
Immunization Program Managers, Local Health Departments

FROM: Karen Hess, Manager 
Vaccine Services Group

THRU: Jack C. Sims, Manager 
Immunization Branch

DATE: March 19, 2010

SUBJECT: Texas Vaccines for Children Program: 13-Valent Pneumococcal Conjugate Vaccine Implementation

On February 24, 2010, the Advisory Committee on Immunization Practices (ACIP) voted on recommendations for the new 13-valent pneumococcal conjugate vaccine (PCV13) among infants and children. The Centers for Disease Control and Prevention (CDC) has announced plans to immediately replace the 7-valent product (PCV7) with PCV13 for the Vaccines for Children program (VFC), and has updated the VFC resolution to reflect the new recommendations.

Texas Vaccines for Children providers may begin receiving PCV13 in vaccine shipments as early as March 24th. Table 1 below outlines the ACIP/CDC recommended PCV schedule and dosage intervals. Please note that the recommendations include all children 2 through 59 months of age, and include several notable enhancements to the past VFC Resolution guidelines. These include (1) recommendations for children 60 through 71 months of age who have underlying medical conditions that increase their risk of pneumococcal disease or complications; (2) a single supplemental dose of PCV13 for all children 14 through 59 months of age who have received four doses of PCV7; and (3) a single supplemental PCV13 dose for children who have underlying medical conditions through 71 months of age, including children who have previously received the 23-valent pneumococcal polysaccharide vaccine (PPSV23).

Eligible groups

- All children at least six weeks through 59 months of age and children 60 through 71 months with certain underlying medical conditions listed in the table below.
- Children 6 through 18 years of age who are at increased risk for invasive pneumococcal disease because of sickle cell disease, HIV-infection, or other immunocompromising condition.

3/19/2010

Recommended Pneumococcal Conjugate Vaccine Schedule and Dosage Intervals

Table 1. Recommended schedules for administering doses of PCV13 among children who have not previously received PCV7 or PCV13, those incompletely vaccinated with PCV7 or PCV13 for age, and supplemental PCV13 immunization

Age at examination (mos)	Vaccination history: total number of PCV7 and/or PCV13 doses received previously	Recommended PCV13 Regimen¹
2 through 6 mos	0 doses	3 doses, 8 weeks apart; fourth dose at age 12–15 mos
	1 dose	2 doses, 8 weeks apart; fourth dose at age 12–15 mos
	2 doses	1 dose, 8 weeks after the most recent dose; fourth dose at age 12–15 mos
7 through 11 mos	0 doses	2 doses, 8 weeks apart; third dose at 12–15 mos
	1 or 2 doses before age 7 mo	1 dose at age 7–11 mos, with a second dose at 12–15 mos, ≥ 8 weeks later
12 through 23 mos	0 doses	2 doses, ≥ 8 weeks apart
	1 dose before age 12 mo	2 doses, ≥ 8 weeks apart
	1 dose at ≥ 12 mo	1 dose, ≥ 8 weeks after the most recent dose ²
	2 or 3 doses before age 12 mo	1 dose, ≥ 8 weeks after the most recent dose ²
	4 doses of PCV7 or other age-appropriate, complete PCV7 schedule	1 supplemental dose, ≥ 8 weeks after the most recent dose*
Healthy children 24 through 59 mos	Unvaccinated or any incomplete schedule	1 dose, ≥ 8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate, complete PCV7 schedule	1 supplemental dose, ≥ 8 weeks after the most recent dose*
Children 24 through 71 mos with underlying medical conditions³ (See conditions chart)	Unvaccinated or any incomplete schedule of <3 doses	2 doses, one ≥ 8 weeks after the most recent dose and another dose ≥ 8 weeks later
	Any incomplete schedule of 3 doses	1 dose, ≥ 8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 supplemental dose, ≥ 8 weeks after the most recent dose*

3/19/2010

Footnotes, Table 1:

- 1) Minimum interval between doses is 8 weeks except for children vaccinated at age <1 year, for whom minimum interval between doses is 4 weeks.
- 2) No additional PCV13 doses are indicated for children 12 through 23 months of age who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age 12 months or older.
- 3) For children who have underlying medical conditions, PCV13 dose is indicated through 71 months of age.

* A single supplemental dose of PCV13 given at least 8 weeks after the last dose of PCV7 is recommended for all children 14 through 59 months of age who have received 4 doses of PCV7 or other age-appropriate, complete PCV7 schedule (fully vaccinated with PCV7). For children who have underlying medical conditions, a supplemental dose is recommended through 71 months of age.

Children 6 through 18 years of age:

A single dose of PCV13 may be administered for children 6 through 18 years of age who are at increased risk for invasive pneumococcal disease (see conditions chart), regardless of whether they have previously received PCV7 or PPSV23.

For complete ACIP provisional recommendations go online to:

<http://www.cdc.gov/vaccines/recs/provisional/downloads/pcv13-mar-2010-508.pdf>

For the updated VFC Resolution go online to:

<http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/0210-pneumo-508.pdf>

Underlying medical conditions that are indications for pneumococcal vaccination among children

Immunocompetent persons	Chronic heart disease*
	Chronic lung disease**
	Diabetes mellitus
	Cerebrospinal fluid leaks
	Cochlear implant
Functional or anatomic asplenia	Sickle cell disease (SCD) and other hemoglobinopathies
	Congenital or acquired asplenia, or splenic dysfunction
Immunocompromised persons	HIV infection
	Chronic renal failure and nephrotic syndrome
	Diseases associated with immunosuppressive chemotherapy, or radiation therapy including malignant neoplasms, leukemias, lymphomas and Hodgkin disease; or solid organ transplantation
	Congenital immunodeficiency***

* Particularly cyanotic congenital heart disease and cardiac failure

** Including asthma if treated with high-dose oral corticosteroid therapy

*** Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease)

3/19/2010

PCV7 Vaccine Return

Unused PCV7 may be returned to McKesson after adequate doses of PCV13 are received. Please use the following steps for the return of PCV7:

- 1) If possible, CDC has requested that providers return PCV7 by early May.
- 2) As with all TVFC vaccine returns, providers should contact their Health Service Region (HSR) or Local Health Department (LHD) representative for return labels.
- 3) Providers should include the Texas Vaccine Loss Report (C-69) in the container with the vaccine, but do not need to forward copies of this form to LHDs or HSRs as with actual vaccine losses.
- 4) These doses do not need to be shipped as viable vaccine; in other words, no ice packs or other temperature protocol are necessary. Vaccines should be securely packed to prevent breakage.
- 5) Providers should send only State TVFC doses back to McKesson. Privately purchased PCV7 should be returned back to Pfizer.

The following chart indicates PCV7 lots distributed to TVFC providers within the past year:

VACCINE	LOT	EXP. DATE	VACCINE	LOT	EXP. DATE
PNU 7	C27701	31-Mar-11	PNU 7	D50002	28-Feb-11
PNU 7	C27703	31-Mar-11	PNU 7	D50003	30-Nov-11
PNU 7	C57963	31-Mar-11	PNU 7	D59297	30-Nov-11
PNU 7	C99082	28-Feb-11	PNU 7	D61921	30-Nov-11
PNU 7	D05879	23-Apr-09	PNU 7	D65510	31-Jan-12
PNU 7	D16280	31-May-11	PNU 7	D66586	31-Jan-12
PNU 7	D16282	28-Jun-11	PNU 7	D66591	31-Jan-12
PNU 7	D18702	31-Jul-11	PNU 7	D74804	29-Feb-12
PNU 7	D21051	28-Jul-11	PNU 7	D75884	24-Dec-09
PNU 7	D22943	30-Jul-11	PNU 7	D75885	29-Feb-12
PNU 7	D23075	31-Jul-11	PNU 7	D78697	29-Feb-12
PNU 7	D24322	31-Jul-11	PNU 7	D81704	29-Feb-12
PNU 7	D33501	30-Sep-11	PNU 7	D84740	31-Mar-12
PNU 7	D34438	31-Aug-11	PNU 7	D84741	31-Mar-12
PNU 7	D36145	30-Sep-11	PNU 7	D88183	31-Mar-12
PNU 7	D36147	30-Sep-11	PNU 7	D90887	30-Apr-12
PNU 7	D37015	30-Sep-11	PNU 7	D93210	30-Apr-12
PNU 7	D37052	30-Sep-11	PNU 7	D93211	30-Apr-12
PNU 7	D39015	30-Sep-11	PNU 7	D94433	30-Apr-12
PNU 7	D39210	30-Apr-12	PNU 7	D94434	30-Apr-12
PNU 7	D46875	31-Oct-11	PNU 7	E07298	30-Sep-13
PNU 7	D48927	31-Oct-11	PNU 7	E13862	30-Sep-13
PNU 7	D48928	31-Oct-11	PNU 7	E15305	30-Sep-13

The CPT code for PCV13 is 90670.

For questions about PCV13 or the PCV7 return process, please contact your local health department or health service region.